查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1497628

细胞治疗市场：按支架、按应用划分 - 2024-2030 年全球预测

Acellular Therapy Market by Scaffold (Cell Laden Hydrogel, Extracellular Matrix (ECM), Fused Deposition Modeling (FDM)), Application (Cardiology, Gastroenterology, Hepatology) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年细胞治疗市场规模为110.7亿美元，预计2024年将达到124.9亿美元，2030年将达到266.5亿美元，复合年增长率为13.37%。

细胞疗法代表再生医学的一个分支，利用细胞成分来修復和再生组织和器官。这些成分包括多种生物分子，如蛋白质、胜肽、生长因子、细胞外基质（ECM）成分和合成的生物活性化合物，但不包括活细胞。该治疗方法利用这些细胞材料的领导潜力来刺激身体的内部修復机制并为组织再生提供支架。 KEYWORD 市场成长受到慢性病盛行率增加、治疗技术进步以及再生医学研究投资增加等因素的影响。此外，政府积极支持再生医学的努力也正在加速细胞疗法的交付。然而，疗法开发的高成本、严格的监管要求以及製造流程的复杂性影响了细胞疗法的开发。细胞治疗市场的潜在机会包括开拓具有增强生物相容性和生物活性的生医材料、与技术公司合作开发先进製造技术以及开拓新兴国家开拓的市场。

主要市场统计
基准年[2023] 110.7亿美元
预测年份 [2024] 124.9亿美元
预测年份 [2030] 266.5亿美元
复合年增长率（%） 13.37%

区域洞察

在美国，特别是美国，细胞疗法已广泛应用于多种临床应用，包括创伤治疗、整形外科治疗以及最近的整容手术。 Acela 疗法在美洲的生产非常复杂，严格的 FDA 法规确保了最高的品质和安全标准。在亚太地区，日本、韩国、中国和印度等国家正成为细胞治疗的重要市场。在这些国家，不断增长的糖尿病人口增加了这些治疗方法在慢性伤口和糖尿病溃疡治疗中的使用。此外，经济成长和医疗保健投资使亚太地区成为新兴的医疗旅游中心，直接影响细胞治疗药物等先进治疗方法的使用。中国和韩国特别投资扩大产能，而日本则以其再生医学创新而闻名。欧洲拥有成熟的细胞治疗市场，拥有用于伤口护理、组织再生和外科应用的先进产品。许多大公司已经进入这个领域并正在推动技术创新。中东和非洲部分地区也认识到了蜂窝产品的潜力，但由于广大地区的经济和医疗保健系统不同，其采用情况并不均衡。欧洲国家拥有符合 EMA 指南的强大生产框架，确保高品质生产。德国、英国、法国等生物技术中心拥有强大的生产能力。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在细胞治疗市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对细胞治疗市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争力的宝贵见解，包括在研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在细胞治疗市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病和与老龄化有关的疾病增加
      • 政府推动再生医学和干细胞研究的倡议
      • 提高无细胞和智慧生医材料的可用性
    • 抑制因素
      • 缺乏熟练的研究人员和有限的报销选择
    • 机会
      • 全球细胞治疗与研发的进展
      • 医院及医疗机构所进行的细胞治疗计划增多
    • 任务
      • 有关再生医学和无细胞疗法的复杂法规
  • 市场区隔分析
    • 支架：细胞外基质支持优先细胞治疗
    • 应用：肿瘤学中针对肿瘤部位的细胞疗法的开发
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 Scaffold 的细胞治疗市场

  • 含有细胞的水凝胶
  • 细胞外基质（ECM）
  • 熔融沈积建模 (FDM)

第七章细胞治疗市场：依应用分类

  • 心臟病学
  • 胃肠病学
  • 肝病学
  • 神经病学
  • 肿瘤学

第八章美洲细胞治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区细胞治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲细胞治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Humacyte 宣布人类去细胞血管 (HAV) 治疗血管创伤患者的 2/3 期研究取得正面结果
    • FDA核准细胞疗法 Lantidra 用于治疗第 1 型糖尿病
    • Humacyte 向乌克兰前线医院供应人类去细胞血管 (HAV)，用于治疗血管创伤
  • 战略分析和建议

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-5A3042B3D68D

[195 Pages Report] The Acellular Therapy Market size was estimated at USD 11.07 billion in 2023 and expected to reach USD 12.49 billion in 2024, at a CAGR 13.37% to reach USD 26.65 billion by 2030.

Acellular therapy represents a branch of regenerative medicine that utilizes acellular components with the goal of repairing or regenerating tissues and organs. These components can include various biomolecules such as proteins, peptides, growth factors, extracellular matrix (ECM) components, and synthetic bioactive compounds but lack any living cells. This form of therapy harnesses the instructive potential of these acellular materials to stimulate the body's intrinsic repair mechanisms or to provide a scaffold for tissue regeneration. The growth of the acellular therapy market is influenced by factors such as the increasing prevalence of chronic diseases, advancements in treatment technology, and growing investments in regenerative medicine research. Further, favorable government initiatives to support regenerative medicine have also accelerated the provision of acellular therapy. However, the high cost of therapy development, stringent regulatory requirements, and the complexity of the manufacturing process impact the acellular therapy development. Potential opportunities within the acellular therapy market include the development of biomaterials with enhanced biocompatibility and bioactivity, collaboration with technology companies for advanced manufacturing techniques, and exploring untapped markets in developing countries.

KEY MARKET STATISTICS
Base Year [2023] USD 11.07 billion
Estimated Year [2024] USD 12.49 billion
Forecast Year [2030] USD 26.65 billion
CAGR (%) 13.37%

Regional Insights

The Americas, particularly the United States, have witnessed widespread adoption of acellular therapy across multiple clinical applications, including wound healing, orthopedic treatments, and, increasingly, cosmetic procedures. The production of acellular therapies in the Americas is highly sophisticated, with stringent FDA regulations ensuring the highest quality and safety standards. In the APAC region, countries such as Japan, South Korea, China, and India are emerging as significant markets for acellular therapy. These countries are seeing increasing use of these therapies in managing chronic wounds and diabetic ulcers due to a growing diabetic population. Further, growing economies and healthcare investments have seen the APAC become a burgeoning medical tourism hub, directly impacting the use of advanced therapies such as acellular therapeutics. China and South Korea are particularly invested in scaling up production capacity, and Japan is known for its innovation in regenerative medicine. Europe has a well-established acellular therapy market, with advanced products used in wound care, tissue regeneration, and surgical applications. The presence of a number of leading companies here drives innovation in the sector. The Middle East and parts of Africa are also recognizing the potential for acellular products; however, their adoption is varied due to differing economic and healthcare systems within the vast region. European countries have robust production frameworks governed by EMA guidelines, which ensure high-quality production. Biotechnology hubs in countries including Germany, the UK, and France have strong production capabilities.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Acellular Therapy Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing prevalence of chronic diseases and age-related conditions
      • Government initiatives to propel regenerative medicine and stem cell research
      • Increased availability of acellular and smart biomaterials
    • Market Restraints
      • Lack of skilled research personnel and limited reimbursement options
    • Market Opportunities
      • Advancements and R&D in acellular therapy worldwide
      • Rising number of acellular therapy projects undertaken by hospitals and medical entities
    • Market Challenges
      • Complex regulations pertaining to regenerative medicine and acellular therapies
  • Market Segmentation Analysis
    • Scaffold: Preference for extracellular matrix to support acellular therapy
    • Application: Development of acellular therapy designed to target oncology tumor sites
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Acellular Therapy Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Acellular Therapy Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma

Humacyte, Inc. unveiled promising results from its pivotal V005 Phase 2/3 study concerning the application of the Human Acellular Vessel (HAV) for emergency vascular trauma repair. This single-arm clinical trial demonstrated that HAV displayed a superior performance, with higher patency rates and notably fewer occurrences of amputation and infection when juxtaposed with historical data on synthetic vascular grafts. [Published On: 2023-09-12]

FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes

The U.S. Food and Drug Administration (FDA) has greenlit Lantidra (donislecel-jujn), a pioneering cellular therapy treatment for adults with type 1 diabetes who consistently struggle to reach their target HbA1c levels due to recurrent severe hypoglycemia, despite undergoing rigorous diabetes management and education. Engineered as the first allogeneic pancreatic islet cell therapy sanctioned by the FDA, Lantidra facilitates insulin regulation through the delivery of allogeneic islet beta cells. [Published On: 2023-06-29]

Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries

Humacyte, Inc. a pioneering clinical-stage biotech firm specializing in the development of universally implantable bioengineered human tissues, has initiated a humanitarian project to distribute its revolutionary Human Acellular Vessels (HAVs) to several Ukrainian hospitals for critical vascular repair treatment in both civilians and military personnel suffering from vascular injuries. The inaugural batch of HAVs, designed as engineered, off-the-shelf vessels for a variety of vascular treatments, has embarked for Ukraine, targeting six medical facilities across cities including Kyiv and Kharkiv. [Published On: 2022-05-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Acellular Therapy Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Acellular Therapy Market, highlighting leading vendors and their innovative profiles. These include Allergan Inc. by Abbvie Inc., AlloSource, Aziyo Biologics, Baxter International, Becton, Dickinson and Company, BioHorizons, Inc., EnColl Corporation, Engitix Ltd, Fidia Farmaceutici S.p.A, GSK PLC, Humacyte, Inc., In2Bones Global by CONMED Corporation, Integra LifeSciences Corporation, LifeNet Health, MiMedx Group, Organicell Regenerative Medicine, Inc., Organogenesis Holdings Inc., Reprise Biomedical, Inc., Sanofi S.A., Smith & Nephew PLC, Stryker Corporation, Tissue Regenix, Vascudyne, Inc., and Zimmer Biomet.

Market Segmentation & Coverage

This research report categorizes the Acellular Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Scaffold
    • Cell Laden Hydrogel
    • Extracellular Matrix (ECM)
    • Fused Deposition Modeling (FDM)
  • Application
    • Cardiology
    • Gastroenterology
    • Hepatology
    • Neurology
    • Oncology
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of chronic diseases and age-related conditions
      • 5.1.1.2. Government initiatives to propel regenerative medicine and stem cell research
      • 5.1.1.3. Increased availability of acellular and smart biomaterials
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of skilled research personnel and limited reimbursement options
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements and R&D in acellular therapy worldwide
      • 5.1.3.2. Rising number of acellular therapy projects undertaken by hospitals and medical entities
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulations pertaining to regenerative medicine and acellular therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Scaffold: Preference for extracellular matrix to support acellular therapy
    • 5.2.2. Application: Development of acellular therapy designed to target oncology tumor sites
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Acellular Therapy Market, by Scaffold

  • 6.1. Introduction
  • 6.2. Cell Laden Hydrogel
  • 6.3. Extracellular Matrix (ECM)
  • 6.4. Fused Deposition Modeling (FDM)

7. Acellular Therapy Market, by Application

  • 7.1. Introduction
  • 7.2. Cardiology
  • 7.3. Gastroenterology
  • 7.4. Hepatology
  • 7.5. Neurology
  • 7.6. Oncology

8. Americas Acellular Therapy Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Acellular Therapy Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Acellular Therapy Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Humacyte Announces Positive Top-Line Results from Phase 2/3 Trial of Human Acellular Vessel (HAV) in Treatment of Patients with Vascular Trauma
    • 11.3.2. FDA Approves Lantidra, a Cellular Therapy for Type 1 Diabetes
    • 11.3.3. Humacyte to Provide Human Acellular Vessels (HAVs) to Front-line Hospitals in Ukraine for Treatment of Vascular Trauma Injuries
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. ACELLULAR THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. ACELLULAR THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ACELLULAR THERAPY MARKET DYNAMICS
  • FIGURE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ACELLULAR THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL ACELLULAR THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CELL LADEN HYDROGEL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY EXTRACELLULAR MATRIX (ECM), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY FUSED DEPOSITION MODELING (FDM), BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY HEPATOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY NEUROLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL ACELLULAR THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 28. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 29. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 30. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 31. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 32. AMERICAS ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 34. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. ARGENTINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 38. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 39. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. BRAZIL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 42. CANADA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 43. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 44. CANADA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 45. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 46. MEXICO ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 47. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. MEXICO ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 50. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 51. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 52. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 54. UNITED STATES ACELLULAR THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 62. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. AUSTRALIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 66. CHINA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 67. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 68. CHINA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 69. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 70. INDIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 71. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. INDIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 74. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 75. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 76. INDONESIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 77. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 78. JAPAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 79. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. JAPAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 82. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 83. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 84. MALAYSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 86. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. PHILIPPINES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 90. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 91. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 92. SINGAPORE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 94. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 96. SOUTH KOREA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 97. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 98. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 99. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. TAIWAN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 102. THAILAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 103. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 104. THAILAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 105. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 106. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 107. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. VIETNAM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA ACELLULAR THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 115. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 116. DENMARK ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 117. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. DENMARK ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 120. EGYPT ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 121. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 122. EGYPT ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 123. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 124. FINLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 125. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. FINLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 128. FRANCE ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 129. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. FRANCE ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 132. GERMANY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 133. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. GERMANY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 136. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 137. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. ISRAEL ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 140. ITALY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 141. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. ITALY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 144. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 146. NETHERLANDS ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 147. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 148. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 149. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. NIGERIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 152. NORWAY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 153. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. NORWAY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 156. POLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 157. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. POLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 160. QATAR ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 161. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 162. QATAR ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 163. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 164. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 165. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. RUSSIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 168. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 170. SAUDI ARABIA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH AFRICA ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 176. SPAIN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 177. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 178. SPAIN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 179. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 180. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 181. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. SWEDEN ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 184. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. SWITZERLAND ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 188. TURKEY ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 189. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. TURKEY ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2018-2023 (USD MILLION)
  • TABLE 196. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY SCAFFOLD, 2024-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. UNITED KINGDOM ACELLULAR THERAPY MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. ACELLULAR THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 200. ACELLULAR THERAPY MARKET, FPNV POSITIONING MATRIX, 2023